November 18, 2025 — Carlsbad, California — Leads & Copy —
Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF) has announced its financial results for the third quarter ended September 30, 2025, showcasing sustained revenue performance and the commercial launch of two new product platforms.
The company reported that Q3 2025 marks the fifth consecutive quarter with sales exceeding $4.4 million. Cumulative sales for the first nine months of 2025 were up $484,698 over the same period last year.
Aurora Spine also achieved a second consecutive quarter of positive EBITDAC, with $165,600 in Q3 2025 and $141,745 in the previous quarter.
In Q3 2025, the company commercially launched the DEXA-L™ Anterior Lumbar Interbody Fusion Device and the Hydra ARO Lumbar Fusion System, a facet fusion device. Both products generated initial sales during the quarter.
CEO Trent Northcutt noted that the third quarter was a period of transition, with the integration of the DEXA-L and Hydra ARO product platforms. He added that initial feedback on the new product launches has been positive and should act as growth catalysts for Aurora Spine in the coming years.
Northcutt also said he is confident in the company’s proprietary product platforms, which are revolutionizing the spinal pain industry through minimally invasive procedures. The company aims to expand its sales team and educate interventionalists and surgeons on the benefits of Aurora Spine’s products, including faster recovery times and better patient outcomes.
CFO Chad Clouse commented that the company is operating efficiently, focusing on collections and expense control, and is sufficiently capitalized to pursue growth opportunities.
Total revenues for Q3 2025 were $4.43 million, a 7.1% decrease compared to $4.77 million in the same quarter last year, due to the transition from a third-party lumbar screw to the Osteo Onyx lumbar product. Sales of lumbar screws decreased 30% from Q1 as the company worked with facilities and doctors to complete the transition.
Gross margin on total revenues was 60.9% for Q3 2025, compared to 60.5% in Q3 2024, attributed to more direct sales reducing distributor commissions.
Total operating expenses were $2.81 million for Q3 2025, consistent with the third quarter of 2024. This included $0.267 million of non-cash expenses, compared to $0.266 million of non-cash expenses. Higher marketing expenses were offset by a decrease in G&A and consulting fees.
EBITDAC was $165,600 for Q3 2025, compared to $380,117 in the third quarter of 2024, reflecting lower revenue levels.
The net loss for Q3 2025 was $(0.142) million, compared to income of $0.070 million in the same quarter of 2024. Basic and diluted net loss per share was $(0.00) per share in Q3 2025 and $0.00 per share for Q3 2024.
A teleconference replay of the call will be available until November 25, 2025, at (855) 669-9658 or (412) 317-0088, replay access code 1704277. Additionally, a replay of the webcast will be available at https://app.webinar.net/P8Y3l3qWdNg for 90 days.
Aurora Spine Corporation designs and manufactures minimally invasive implants and regenerative solutions for spinal and interventional pain procedures. From its patented DEXA™ bone-density-matched implants to its ZIP™ interspinous systems and SiLO™ SI fusion platform, Aurora Spine is dedicated to advancing patient-specific, surgeon-driven innovations that restore stability, relieve pain, and deliver dependable fusion outcomes.
Contact:
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
Adam Lowensteiner
Lytham Partners
(646) 829-9702
Email: asapf@lythampartners.com
Source: Aurora Spine Corporation
